Drugs / recombinant human B-type natriuretic peptide
recombinant human B-type natriuretic peptide
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT05723315 | Feb 2023 → Dec 2024 | ST-elevation myocardial infarction | Henan Institute of Cardiovascular Epidemiology | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | recombinant human B-type natriuretic peptide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05723315 ↗ |
| Modality | Peptide | “recombinant human B-type natriuretic peptide” NCT05723315 ↗ |
| Route | Intravenous | “first at 1.5μg /kg intravenous load” NCT05723315 ↗ |